Enhanced Vancomycin Hemodialysis model now available in DoseMeRx!Learn more →

Clinical Advisory Board

Meet the experts advising DoseMeRx in the pursuit of clinical excellence and governance.

(Chair) Marc H. Scheetz, PharmD, MSc, FCCP, FCP

Professor at Midwestern University, & Director of the Pharmacometric Center of Excellence at Midwestern University

Dr. Marc Scheetz is a Professor at Midwestern University in the Chicago College of Pharmacy, holds a joint appointment in the Department of Pharmacology, College of Graduate Studies, & is the Director of the Pharmacometric Center of Excellence at Midwestern University. He practices clinically as an ID pharmacist at Northwestern Memorial Hospital & serves as the Director for the Post-Doctoral Fellowship Program in Infectious Diseases Pharmacotherapy. He has authored over 190 original research manuscripts & review articles in the area of anti-infective pharmacokinetics & pharmacodynamics & serves as a reviewer for several journals. His primary research interest lies in the interface of the pharmacokinetic/pharmacodynamic interaction. He is particularly interested in assessing modifiable pharmacologic variables in the treatment of infectious diseases & identifying optimal exposures against the backdrop of toxicity. Dr. Scheetz attained a Doctorate of Pharmacy from Butler University, a Masters of Science in Clinical Investigation degree at Northwestern University, & completed his pharmacy practice residency & an ID fellowship at Northwestern Memorial Hospital.

Luigi Brunetti

Luigi Brunetti, PharmD, MPH, PhD, BCPS, BCGP

Associate Professor, Ernest Mario School of Pharmacy, Rutgers University

Dr. Brunetti is an Associate Professor at the Ernest Mario School of Pharmacy, Rutgers University and a Clinical Pharmacy Specialist in Internal Medicine at Robert Wood Johnson University Hospital Somerset, New Jersey. He serves as the Co-Director of the Center of Excellence in Pharmaceutical Translational Research and Education (CEPTRE). He received his Doctor of Pharmacy from the Philadelphia College of Pharmacy and a Master of Public Health degree with a concentration in epidemiology at the University of Medicine and Dentistry of New Jersey. His research interests include drug dosing in special populations and the influence of cardiometabolic disease on drug response.

Will Musick

Will Musick, PharmD, BCIDP

Infectious Diseases Clinical Specialist, Houston Methodist Hospital

Dr. Musick is Infectious Diseases Clinical Specialist at Houston Methodist Hospital (HMH) in Houston,TX. He focuses on the Solid-Organ Transplant and Critically Ill populations. He developed and directs the PGY2 Infectious Diseases residency program at HMH and holds adjunct faculty appointments to the University of Houston College of Pharmacy and the University of Texas College of Pharmacy. His professional interests include teaching/training residents and students and researching atypical infections and CMV in the solid-organ transplant population.

Shivani Patel

Shivani Patel, PharmD, BCPS

Pharmacy Administrative Specialist – Antimicrobial Stewardship, Houston Methodist Health System

Dr. Patel is a Pharmacy Administrative Specialist – Antimicrobial Stewardship at Houston Methodist Health System. She is responsible for leading system-wide antimicrobial stewardship, quality improvement, and cost savings initiatives. She received her Doctor of Pharmacy from the University of North Carolina at Chapel Hill and completed her residency training at Vanderbilt University Medical Center in Nashville, TN. Her research interests include improving antibiotic utilization and evaluating the utility of rapid diagnostics and clinical decision support in the clinical setting.

Ethan Smith, PharmD, BCIDP

Clinical Pharmacist, UCLA Health Antimicrobial Stewardship Program, Ronald Reagan UCLA Medical Center

Dr. Smith is the adult/transplant infectious diseases clinical pharmacist lead at Ronald Reagan UCLA Medical Center in Los Angeles, California. He serves as a PGY-1/PGY-2 residency preceptor for infectious diseases/antimicrobial stewardship. He is an Assistant Clinical Professor of Pharmacy for the University of California San Francisco School of Pharmacy and Adjunct Assistant Professor of Pharmacy Practice for the University of Southern California School of Pharmacy. His primary interests include infections in the immunocompromised host, beta-lactam/linezolid therapeutic drug monitoring, beta-lactam allergies, and more recently, clinical and therapeutic treatment options in COVID-19.

DoseMeRx Clinical Advisory Board Jeffrey Cies

Jeffrey J. Cies, PharmD, MPH, BCPS-AQ ID, BCPPS, FCCP, FCCM, FPPA

Pharmacy Clinical Coordinator, Critical Care and Infectious Diseases, St. Christopher’s Hospital

Jeff received his Doctor of Pharmacy degree from the Virginia Commonwealth University and his Masters in Public Health from Temple University, with a concentration is Biostatistics and Epidemiology. His research focuses on describing anti-microbial pharmacokinetic and pharmacodynamic changes in critically ill children, children with cystic fibrosis and children with cancer in addition to beta-lactam therapeutic drug management to provide insight regarding appropriate dosing regimens for these vulnerable populations.

Erica Sievert, PharmD, MBA Candidate

Regional Director of Pharmacy, New England Life Care

Dr. Sievert is the Regional Director of Pharmacy at New England Life Care, a comprehensive home infusion therapy, home infusion nursing and specialty pharmacy. She is responsible for leading the clinical and operational pharmacy department. She received her Doctor of Pharmacy from the Massachusetts College of Pharmacy in Worcester, MA and Bachelor of Science in Mathematics and Computer Science at Ithaca College. Her research interests are in utilizing software tools and data analytics, combined with clinical operations to improve outcomes for the home infusion patient population while reducing readmissions to support New England Life Care’s member hospital cooperative in the New England area.

Jacques Turgeon, BPharm, PhD

Chief Executive Officer, GalenusRx

Dr. Turgeon is the CEO of GalenusRx. Previously, he lead the TRHC Precision Pharmacotherapy Research and Development Institute as Chief Scientific Officer and CEO. He was an Associate Dean and Professor of Pharmaceutics at the University of Florida (UF) College of Pharmacy, and held several leadership positions at the University of Montreal. He is a known expert on pharmacogenetics and drug–drug interactions, particularly among treatments for cardiovascular disease.

Sharmeen Roy_CAB

Sharmeen Roy, PharmD, BCPS

Chief Strategy & Science Officer, DoseMe

Sharmeen’s 20-year career spans pediatric clinical pharmacy, clinical research, pharmacogenomics, and strategic leadership. She received her Doctor of Pharmacy degree from the University of Illinois at Chicago and completed a Pediatric Specialty Pharmacotherapy Residency at Texas Children’s Hospital. She is board certified in pharmacotherapy and holds a certification in pharmacogenomics from University of Florida. Her tenure includes esteemed institutions such as Texas Children’s Hospital, University of Chicago Medical Center, Nicklaus Children’s Hospital, and Miami Cancer Institute. At PipelineRx, she held senior roles, managing large teams and driving client engagement for over 500 hospitals. She is actively involved in CPIC, STRIPE, PIDS, ACCP, ASHP and PPA. Being a practitioner who embraces technology, Sharmeen strategically blends her extensive clinical expertise with cutting-edge innovations, leading the way in enhancing patient care.

(Past Chair) Tom Lodise, PharmD, PhD

Professor, Albany College of Pharmacy and Health Sciences

Dr. Lodise is a Professor at Albany College of Pharmacy and Health Sciences in Albany, New York. He received his Doctor of Pharmacy from Temple University School of Pharmacy and his Doctor of Philosophy in Epidemiology from the State University of New York School of Public Health. Integrating his dual interests in scholarship and patient care, Dr. Lodise’s overall research goal is to quantitatively enhance our current understanding of antimicrobial exposure-response relationships in patients with invasive bacterial infections. His research encompasses three interrelated domains: pharmacokinetics (PK)/pharmacodynamics (PD), epidemiology, and outcomes.

Why should you choose DoseMeRx?

trusted by clincians
1:1 customer support

Request a demo

See how easy DoseMeRx is to operate and integrate into your workday.

Request a demo below. You can also phone us on +1 (832) 358-3308 or email hello@dosemehealth.com.

HIPAA Privacy Statement | Privacy policy | DoseMe & the GDPR | Copyright © 2012 - 2024 DoseMe Pty Ltd. All Rights Reserved.
DoseMe® is a registered trademark of DoseMe Pty Ltd. DoseMeRx℠ and DoseMe℞℠ are service marks of DoseMe LLC.